← All Benitec Biopharma INC filings

Benitec Biopharma INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
BNTC
Benitec Biopharma INC
10-K/A: Benitec Biopharma Amends 10-K, Boosts Cash Reserves
Benitec Biopharma Inc. filed an amended annual report for fiscal year 2025 to include auditor signatures and updated certifications, while reporting increased cash and continued operational losses.
NASDAQ
BNTC
Benitec Biopharma INC
10-K: Benitec Biopharma Restates Financials, Advances OPMD Therapy
Benitec Biopharma Inc. restated prior period financial statements due to share-based compensation errors, while continuing to advance its lead OPMD gene therapy, BB-301, through clinical trials.
NASDAQ
BNTC
Benitec Biopharma INC
10-K: Benitec Biopharma Inc. Files 10-K, Reports Progress on OPMD Treatment
Benitec Biopharma Inc. has filed its annual 10-K report, highlighting advancements in its OPMD treatment program and financial activities.